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p38 mitogen-activated protein kinases
=====================================

p38α (originally named p38) was identified and cloned as a 38 kDa protein that was tyrosine-phosphorylated in response to LPS stimulation in mammalian cells ^[@ref-1],\ [@ref-2]^. Sequence comparison, on the day p38α was cloned, revealed that it belonged to the mitogen-activated protein kinase (MAPK) family and that a *Saccharomyces cerevisiae* osmotic response protein kinase HOG1 was a p38α homologue ^[@ref-3]--\ [@ref-5]^. p38α was also named cytokine suppressive drug binding protein (CSBP) because it was identified as the target of a series of anti-inflammatory pyridinyl-imidazole compounds and as reactivating kinase (RK) because it phosphorylated and activated MK2 ^[@ref-3]--\ [@ref-5]^. There are four members of the p38 group of MAPKs encoded by four different genes in mammals: p38α ( *MAPK14*, chromosome 6p21.31 in humans), p38β ( *MAPK11*, SAPK2b, Chr22q13.33) ^[@ref-6]^, p38γ ( *MAPK12*, ERK6, SAPK3, Chr22q13.33) ^[@ref-7],\ [@ref-8]^, and p38δ ( *MAPK13*, SAPK4, Serk4, Chr6p21.31) ^[@ref-9],\ [@ref-10]^. As can be surmised from their chromosomal locations, *MAPK14*/p38α and *MAPK13*/p38δ are physically close and separated by just over 15 kb, as are *MAPK12*/p38β and *MAPK11*/p38γ, which are separated by less than 2 kb. All the p38s contain a conserved Thr--Gly--Tyr (TGY) dual phosphorylation motif within the kinase activation loop, and both Thr and Tyr phosphorylation are necessary to fully activate the kinase ^[@ref-11]^. However, monophosphorylated p38α Thr ^180^ has some kinase activity *in vitro*, but a different substrate specificity, when compared with dual-site phosphorylated p38α ^[@ref-12]^. p38 group members are expressed ubiquitously, but p38γ and p38δ are enriched in certain cell types and tissues, such as p38γ in skeletal muscle and p38δ in the salivary, pituitary, and adrenal glands ^[@ref-13]^. p38β shares more amino acid sequence identity with p38α (\~70%), while p38γ and p38δ share \~60% identity with p38α. p38γ and p38δ also share high sequence homology with cyclin-dependent kinases (CDKs) and are sensitive to some CDK inhibitors ^[@ref-14]^.

Activation and inactivation of p38
==================================

p38α is involved in the response to almost all stressful stimuli, including LPS, UV light, heat shock, osmotic shock, inflammatory cytokines, T cell receptor ligation, glucose starvation, and oncogene activation ^[@ref-2],\ [@ref-4],\ [@ref-5],\ [@ref-15]--\ [@ref-20]^. Under certain circumstances, it is also activated upon growth factor stimulation. It should be noted that the activation of p38 in some cases is cell type specific, since an activating stimulus in one cell type may inhibit p38 in other cell types ^[@ref-21]^. The study of p38 group members other than p38α has been less intensive; however, where it has been examined, the other p38s are frequently co-activated with p38α ^[@ref-22]^.

Like other MAPK signaling pathways, the activation of all p38s is mediated by a kinase cascade: MAPKKK (MAP3K), which activates MAPKK (MAP2K), which in turn activates MAPK. The MAP2K kinases MKK3 and MKK6 are the major upstream kinases for p38 activation ^[@ref-23]--\ [@ref-25]^. Although MKK3 and MKK6 phosphorylate most p38 isoforms *in vitro*, selective activation and substrate specificity have been observed *in vivo* ^[@ref-26]^. MKK4 has also been reported to phosphorylate p38α and p38δ in specific cell types ^[@ref-9]^. A number of MAP3Ks have been reported to participate in p38 activation including TAK1 ^[@ref-27]^, ASK1 ^[@ref-28]^, DLK ^[@ref-29]^, and MEKK4 ^[@ref-29],\ [@ref-30]^. Low-molecular-weight GTP-binding proteins in the Rho family, such as Rac1 and Cdc42, can activate p38 through binding to MEK1 or MLK1, which function as upstream activators of MAP3K ^[@ref-31],\ [@ref-32]^.

p38α can also be activated by MAP2K-independent mechanisms. TAB1 (TAK1-binding protein 1) directly interacts with p38α and can promote trans autophosphorylation on Thr ^180^ and Tyr ^182^ and thus full activation of p38α ^[@ref-33]^. A subsequent study revealed that autophosphorylation of Thr ^180^ and Tyr ^182^ requires a conserved Thr ^185^ residue ^[@ref-34]^. TAB1-dependent p38α activation has been implicated in ischemic myocardial injury and T cell anergy ^[@ref-35],\ [@ref-36]^. TAB1 is also claimed to play a role in Sestrin-mediated p38α activation ^[@ref-12]^. Another MAP2K-independent activation is mediated by ZAP70 after T cell receptor ligation. ZAP70 can directly phosphorylate p38α/β on Tyr ^323^ ^[@ref-18]^, leading to autophosphorylation on Thr ^180^, one of the dual phosphorylation sites. As discussed, mono-Thr ^180^ phosphorylated p38 still has some kinase activity ^[@ref-37]^, and loss of ZAP70-mediated p38 activation in p38αβ ^Y323F^ double knock-in mice reduces autoimmunity and inflammation in several autoimmune disease models ^[@ref-38]--\ [@ref-40]^. Interestingly, p38α also phosphorylates ZAP70, resulting in a decrease in the size and persistence of the T cell receptor signaling complex, and therefore acts as a feedback regulator of ZAP70 ^[@ref-41]^.

Conversely, de-phosphorylation of both threonine and tyrosine residues in the activation loop inactivates MAPKs, and this is mainly carried out by dual-specificity phosphatases of the MAPK phosphatase (MKP)/dual specificity phosphatase (DUSP) family ^[@ref-42]^. Although several MKPs have been reported to dephosphorylate p38α, MKP1/DUSP1, MKP5/DUSP10, MKP8/DUSP26, and DUSP8 are more potent inhibitors of p38α and JNK than ERK ^[@ref-43]^. A recent report showed that DUSP12 is also a p38α phosphatase ^[@ref-44]^. While there are a number of p38α DUSPs, no DUSP for p38γ or p38δ has been reported, and these two p38s are resistant to several known p38α MKPs such as MKP1, 3, 5, and 7 ^[@ref-45]^. p38α-dependent upregulation of MKP1 was reported and is believed to be part of a negative feedback loop of p38α activation ^[@ref-46]^. Other types of phosphatases have also been reported to target p38 MAPKs, such as CacyBP/SIP ^[@ref-47]^, Wip1 ^[@ref-48]^, and PP2C ^[@ref-49],\ [@ref-50]^. The substrate specificity between p38 and phosphatases and the related physiological functions *in vivo* still need further investigation. p38γ has also been reported to be degraded by a p38/JNK/ubiquitin-proteasome-dependent pathway, which represents an additional mechanism by which p38 kinases may cross regulate each other ^[@ref-51]^. Yet other ways of regulating p38 are suggested from studies in *Caenorhabditis elegans*, where a genetic screen for resistance against bacterial infection identified RIOK-1, an atypical serine kinase and human RIO kinase homolog, as a suppressor of the p38 pathway ^[@ref-52]^. As RIOK-1 is a transcriptional target of the p38 pathway in *C. elegans*, this suggests that RIOK-1 is part of a negative feedback loop. A brief summary of the p38 pathway is shown in [Figure 1](#f1){ref-type="fig"}.

![A diagram of the p38 pathway.\
MKP, mitogen-activated protein kinase phosphatase; TAB1, TAK1-binding protein 1; Tyr, tyrosine.](f1000research-9-24364-g0000){#f1}

Downstream substrates of p38
============================

Protein kinases
---------------

The p38 MAPK cascade does not end at p38. Members of the MAPK-activated protein kinase (MAPKAPK) family such as MK2, MK3, and MK5 (PRAK) are all p38 substrates ^[@ref-3],\ [@ref-4],\ [@ref-53]--\ [@ref-55]^. The MKs have a broad range of substrates that extend the range of functions regulated by p38 kinases. Mitogen- and stress-activated protein kinase-1/2 (MSK1/2), which are important for CREB activation and chromosome remodeling, have also been identified as substrates of p38α ^[@ref-56]^. MNK1/2, kinases that phosphorylate the eukaryotic initiation factor-4e (eIF-4E), are phosphorylated by p38α ^[@ref-57],\ [@ref-58]^. p38α has also been reported to inactivate murine GSK3β by phosphorylating Ser ^389^, and since GSK3β is required for the continuous degradation of β-catenin in the Wnt signaling pathway, this can lead to an accumulation of β-catenin ^[@ref-59],\ [@ref-60]^. It was also reported that p38δ negatively regulates insulin secretion by catalyzing an inhibitory phosphorylation of PKD1 ^[@ref-61]^. A number of p38 protein kinase substrates are summarized in [Table 1](#T1){ref-type="table"}.

###### Substrates of p38 group members -- kinases.

  ---------------------------------------------------------------------------------------------------------------------------
  Substrate   Kinase               Function                           References
  ----------- -------------------- ---------------------------------- -------------------------------------------------------
  MAPKAPK2\   p38α, p38β, p38γ,\   Activates the kinase substrate     Freshney NW *et al*., *Cell,* 1994 ^[@ref-4]^\
  (MK2)       p38δ                                                    Rouse J *et al*., *Cell,* 1994 ^[@ref-3]^

  MAPKAPK3\   p38α, p38β, p38γ,\   Activates the kinase substrate     McLaughlin MM *et al*., *J Biol Chem,*\
  (MK3)       p38δ                                                    1996 ^[@ref-54]^

  MNK1/2      p38α                 Activates the kinase substrate     Fukunaga R *et al., EMBO J,* 1997 ^[@ref-58]^\
                                                                      Waskiewicz AJ *et al., EMBO J,*\
                                                                      1997 ^[@ref-57]^

  MSK1/2      p38α                 Activates the kinase substrate     Deak M *et al., EMBO J,* 1998 ^[@ref-56]^\
                                                                      Pierrat B *et al., J Biol Chem,* 1998 ^[@ref-77]^

  PAK6        p38α                 Activates the kinase substrate     Kaur R *et al., J Biol Chem,* 2005 ^[@ref-78]^

  PIP4Kb      p38α                 Inactivates the kinase substrate   Jones DR *et al., Mol Cell,* 2006 ^[@ref-79]^

  RPAK\       p38α, p38β           Activates the kinase substrate     New L *et al., EMBO J,* 1998 ^[@ref-55]^
  (MK5)                                                               

  PKCε        p38α, p38β           Completes cytokinesis              Saurin AT *et al., Nat Cell Biol,* 2008 ^[@ref-80]^

  GSK3β       p38α                 Inactivates the kinase\            Bikkavilli RK *et al., J Cell Sci,* 2008 ^[@ref-60]^\
                                   substrate, activates Wnt\          Thornton TM *et al., Science,* 2008 ^[@ref-59]^
                                   pathway.                           
  ---------------------------------------------------------------------------------------------------------------------------

GSK3β, glycogen synthase kinase 3 beta; MAPKAPK, mitogen-activated protein kinase activated protein kinase; MSK1/2, mitogen- and stress-activated protein kinase; PAK6, p21-activated kinase 6; PIP4Kb, phosphatidylinositol 5 phosphate 4-kinase; PKCε, protein kinase C epsilon type.

Transcription factors
---------------------

p38 targets a large number of transcription factors, including myocyte-specific enhancer factor 2 (MEF2) family members, cyclic AMP-dependent transcription factor 1, 2, and 6 (ATF-1/2/6), CHOP (growth arrest and DNA damage inducible gene 153, or GADD153), p53, C/EBPβ, MITF1, DDIT3, ELK1/4, NFAT, and STAT1/4. p38 phosphorylation of transcription factors predominantly leads to enhanced transcriptional activity. However, in some cases, it represses transcription, and this is summarized in [Table 2](#T2){ref-type="table"}. Transcription factor phosphorylation by p38 is often stimulus and cell type dependent and plays a role in the cellular response to inflammation, DNA damage, metabolic stress, and many other stresses ^[@ref-62]--\ [@ref-76]^. The effects of p38 on transcription seem to constitute the major part of p38's responses to stress stimuli.

###### Substrates of p38 group members -- transcription factors.

  ------------------------------------------------------------------------------------------------------------------------
  Substrate   Kinase         Function                             References
  ----------- -------------- ------------------------------------ --------------------------------------------------------
  ATF2        p38α, p38β,\   Enhances transcriptional activity    Cuenda A *et al*., *EMBO J,* 1997 ^[@ref-81]^\
              p38γ, p38δ                                          Jiang Y *et al*., *J Biol Chem,* 1997 ^[@ref-9]^

  C/EBPα      p38α           Enhances transcriptional activity    Qiao L *et al*., *J Biol Chem,* 2006 ^[@ref-82]^

  C/EBPβ      p38α           Enhances transcriptional activity    Engelman JA *et al*., *J Biol Chem,* 1998 ^[@ref-83]^

  C/EBPε      p38α           Enhances transcriptional activity    Williamson EA *et al*., *Blood,* 2005 ^[@ref-84]^

  CHOP        p38α, p38β     Enhances transcriptional activity    Wang XZ *et al*., *Science,* 1996 ^[@ref-68]^

  E2F4        p38α           Enhances transcriptional activity    Morillo SM *et al*., *Mol Cell Biol,* 2012 ^[@ref-85]^

  Elk-1       p38α           Enhances transcriptional activity\   Janknecht R *et al*., *EMBO J,* 1997 ^[@ref-67]^\
                             in specific cell types               Whitmarsh AJ *et al*., *Mol Cell Biol,*\
                                                                  1997 ^[@ref-66]^

  ERα         p38α           Enhances nuclear localization\       Lee H *et al*., *Mol Cell Biol,* 2002 ^[@ref-86]^
                             and transcriptional activity         

  Fos         p38α, p38β,\   Enhances transcriptional activity    Tanos T *et al*., *J Biol Chem,* 2005 ^[@ref-87]^
              p38γ, p38δ                                          

  FOXO3a      p38α           Enhances nuclear relocalization      Ho KK *et al., J Biol Chem,* 2012 ^[@ref-88]^

  GR          p38α           Enhances transcriptional activity    Miller AL *et al., Mol Endocrinol,*\
                                                                  2005 ^[@ref-89]^

  IUF1        p38α, p38β     Enhances transcriptional activity    Macfarlane WM *et al., J Biol Chem,* 1997 ^[@ref-90]^

  JDP2        p38α           N/D                                  Katz S *et al., Biochem J,* 2002 ^[@ref-91]^

  c-JUN       p38α, p38β,\   Enhances transcriptional activity    Humar M *et al., Int J Biochem Cell*\
              p38γ                                                *Biol,* 2007 ^[@ref-92]^

  MafA        p38α, p38β,\   Enhances transcriptional activity    Sii-Felice K *et al., FEBS Lett,* 2005 ^[@ref-93]^
              p38γ, p38δ                                          

  MEF2A       p38α, p38β,\   Enhances transcriptional activity    Zhao M *et al., Mol Cell Biol,* 1999 ^[@ref-94]^
              p38δ                                                

  MEF2C       p38α, p38β\    Enhances transcriptional activity    Han J *et al., Nature,* 1997 ^[@ref-62]^
              p38γ, p38δ                                          

  MEF2D       p38α           Enhances recruitment of Ash2L\       Zhao M *et al., Mol Cell Biol,* 1999 ^[@ref-94]^\
                             to muscle-specific promoters         Rampalli S *et al., Nat Struct Mol Biol,*\
                                                                  2007 ^[@ref-73]^

  MITF        p38α           Enhances transcriptional activity    Mansky KC *et al., J Biol Chem,*\
                                                                  2002 ^[@ref-95]^

  MRF4        p38α           Represses transcriptional activity   Suelves M *et al., EMBO J,* 2004 ^[@ref-96]^

  NFATc1      p38α           Enhances transcriptional activity\   Matsumoto M *et al., J Biol Chem,*\
                             and interaction with PU.1            2004 ^[@ref-97]^

  NFATc4      p38α, p38β\    Represses nuclear localization\      Yang TT *et al., Mol Cell Biol,* 2002 ^[@ref-98]^
              p38γ           and transcriptional activity         

  NR4A        p38α           Enhances transcriptional activity    Sekine Y *et al., J Cell Sci,* 2011 ^[@ref-99]^

  Nur77       p38α           Disrupts interaction with p65 and\   Li L *et al., Nat Chem Biol,* 2015 ^[@ref-100]^
                             represses transcriptional activity   

  Osterix     p38α           Enhances recruitment of\             Ortuño MJ *et al., J Biol Chem,*\
                             coactivators                         2010 ^[@ref-101]^

  p53         p38α           Increases protein stability and\     Bulavin DV *et al., EMBO J,* 1999 ^[@ref-69]^
                             apoptosis                            

  Pax6        p38α           Enhances transcriptional activity    Mikkola I *et al., J Biol Chem,* 1999 ^[@ref-102]^

  PPARα       p38α           Enhances transcriptional activity    Barger PM *et al., J Biol Chem,* 2001 ^[@ref-103]^

  SAP1        p38α, p38β\    Enhances transcriptional activity    Janknecht R *et al*., *EMBO J,* 1997 ^[@ref-67]^
              p38γ, p38δ                                          

  Smad3       p38α           Enhances nuclear translocation       Hayes SA *et al*., *Oncogene,* 2003 ^[@ref-104]^

  Snail       p38α           Increases protein stability and\     Ryu KJ *et al*., *Cancer Res,* 2019 ^[@ref-105]^
                             transcriptional activity             

  STAT1       p38α, p38β     Enhances transcriptional activity    Kovarik P *et al*., *Proc Natl Acad Sci*\
                                                                  *U S A,* 1999 ^[@ref-106]^

  STAT4       p38α           Enhances transcriptional activity    Visconti R *et al*., *Blood,* 2000 ^[@ref-107]^

  TEAD4       p38α           Enhances cytoplasmic\                Lin KC *et al*., *Nat Cell Biol,* 2017 ^[@ref-76]^
                             translocation and suppresses\        
                             transcriptional activity             

  Twist1      p38α           Increases protein stability and\     Hong J *et al*., *Cancer Res,* 2011 ^[@ref-108]^
                             transcriptional activity             

  USF1        p38α           Enhances transcriptional activity    Galibert MD *et al*., *EMBO J,* 2001 ^[@ref-71]^

  Xbp1s       p38α           Enhances nuclear translocation\      Lee J *et al*. *, Nat Med,* 2011 ^[@ref-75]^
                             and transcriptional activity         
  ------------------------------------------------------------------------------------------------------------------------

ATF2, activating transcription factor 2; C/EBP, CCAAT/enhancer binding protein; CHOP, CCAAT/enhancer-binding protein homologous protein; ER, estrogen receptor; GR, glucocorticoid receptor; IUF1, insulin upstream factor 1; JDP2, Jun dimerization protein 2; MEF, myocyte-specific enhancer factor; MITF, microphthalmia transcription factor; MRF, muscle regulatory factor; NFAT, nuclear factor of activated T cells; Pax6, paired box 6; PPARα, peroxisome proliferator-activated receptor alpha; TEAD4, TEA domain family transcription factor 4; USF1, upstream transcription factor 1; Xbp1s, spliced form of X-box binding protein 1.

Transcriptional regulators
--------------------------

A large number of transcriptional regulators, including epigenetic enzymes, are substrates of p38, and these are summarized in [Table 3](#T3){ref-type="table"}. The SWI--SNF complex subunit BAF60 is phosphorylated and inactivated by p38 during skeletal myogenesis ^[@ref-109],\ [@ref-110]^, and EZH2, the catalytic component of the Polycomb Repressive Complex 2 (PRC2), was also found to be phosphorylated by p38, particularly in ER-negative breast cancer samples ^[@ref-111]^. Besides its transcriptional function, dATF-2 is also involved in heterochromatin formation, and stress-induced phosphorylation of dATF-2 by p38 disrupts heterochromatin in *Drosophila* ^[@ref-112]^.

###### Substrates of p38 group members -- transcriptional regulators.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                Substrate    Kinase                               Function                                             References
  ------------- ------------ ------------------------------------ ---------------------------------------------------- ---------------------------------------------------
  Chromatin\    BAF60c       p38α, p38β                           Activates transcription of MyoD-\                    Simone C *et al*., *Nat Genet,*\
  remodeling\                                                     target genes                                         2004 ^[@ref-109]^\
  regulators                                                                                                           Forcales SV *et al*., *EMBO J,*\
                                                                                                                       2012 ^[@ref-110]^

  RNF2          p38α         Modulates gene expression and\       Rao PS *et al*., *Proteomics,*\                      
                             histone 2B acetylation               2009 ^[@ref-124]^                                    

  EZH2          p38α         Promotes cytoplasmic localization    Anwar T *et al*., *Nat Commun,*\                     
                                                                  2018 ^[@ref-111]^                                    

  dAFF2         p38α, p38β   Disrupts heterochromatin\            Seong K-H *et al*., *Cell,* 2011 ^[@ref-112]^        
                             formation                                                                                 

  Other\        CRTC2        p38α                                 Enhances nucleocytoplasmic\                          Ma H *et al*., *Mol Cell Biol,* 2019 ^[@ref-125]^
  regulators                                                      transport and represses\                             
                                                                  transcription activity                               

  E47           p38α, p38β   Enhances the formation of MyoD/\     Page JL *et al., J Biol Chem,* .\                    
                             E47 heterodimers                     2004 ^[@ref-126]^\                                   
                                                                  Lluís F *et al*., *EMBO J,* 2005 ^[@ref-127]^        

  HBP1          p38α         Increases protein stability and\     Xiu M *et al*., *Mol Cell Biol,* 2003 ^[@ref-128]^   
                             represses transcription                                                                   

  p18(Hamlet)   p38α, p38β   Increases protein stability and\     Cuadrado A *et al*., *EMBO J,*\                      
                             enhances transcription               2007 ^[@ref-129]^                                    

  PGC-1α        p38α, p38β   Increases protein stability and\     Puigserver P *et al., Mol Cell,*\                    
                             enhances transcription               2001 ^[@ref-130]^                                    

  Rb1           p38α, p38γ   Induces Rb degradation and cell\     Delston RB *et al., Oncogene,*\                      
                             death; suppresses Rb activity and\   2011 ^[@ref-131]^\                                   
                             promotes the G0-to-G1 transition     Tomás-Loba A *et al., Nature,*\                      
                                                                  2019 ^[@ref-14]^                                     

  SRC-3         p38α         Induces SRC-3 degradation and\       Giannì M *et al., EMBO J,* 2006 ^[@ref-132]^         
                             suppresses RARα-dependent\                                                                
                             transcription                                                                             
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CRTC2, CREB-regulated transcription coactivator 2; HBP1, HMG-box transcription factor 1; PGC-1α, peroxisome proliferator-activated receptor gamma co-activator 1 alpha; RAR, retinoic acid receptor; RNF2, ring finger protein 2.

Other substrates
----------------

Given the wide range of responses that p38 is involved in, it is not surprising that many p38 substrates cannot be so easily categorized into groups, and these miscellaneous substrates are summarized in [Table 4](#T4){ref-type="table"}. Some of them are involved in metabolism such as Raptor phosphorylation by p38β, which enhances mTORC1 activity in response to arsenite-stress ^[@ref-113]^, and DEPTOR (mTOR-inhibitory protein) phosphorylation by p38γ and p38δ, leading to its degradation and mTOR hyperactivation ^[@ref-114]^. p38α phosphorylation of Tip60 at Thr ^158^ promotes senescence and DNA-damage-induced apoptosis ^[@ref-115],\ [@ref-116]^. Some p38 substrates are cell death regulators. In the ER stress response, p38α locates to the lysosome and phosphorylates the chaperone-mediated autophagy (CMA) receptor LAMP2A, leading to activation of CMA and thus protecting cells from ER stress-induced death ^[@ref-117]^.

###### Substrates of p38 group members -- others.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                     Substrate          Kinase                                         Function                                                        References
  ------------------ ------------------ ---------------------------------------------- --------------------------------------------------------------- -------------------------------------------------------------
  Cell-cycle\        Cdc25A             p38α                                           Increases protein stability                                     Goloudina A *et al*. *, Cell Cycle,* 2003 ^[@ref-133]^
  regulators                                                                                                                                           

  Cdc25B             p38α               Increases protein stability                    Lemaire M *et al*., *Cell Cycle,* 2006 ^[@ref-134]^             

  Cyclin D1          p38α               Causes ubiquitination and degradation\         Casanovas O *et al*., J Biol Chem *,* 2000 ^[@ref-135]^         
                                        of cyclin D1                                                                                                   

  Cyclin D3          p38α, p38β\        Causes ubiquitination and degradation\         Casanovas O *et al*., *Oncogene,* 2004 ^[@ref-136]^             
                     p38γ, p38δ         of cyclin D3                                                                                                   

  p57kip2            p38α               Enhances interaction with CDKs and\            Joaquin M *et al*., *EMBO J,* 2012 ^[@ref-137]^                 
                                        inhibits CDKs                                                                                                  

  Cell-death\        Bax                p38α                                           Prevents Bcl-2--Bax heterodimer\                                Min H *et al*., *Mol Carcinog,* 2012 ^[@ref-138]^
  regulators                                                                           formation, enhances apoptosis                                   

  BimEL              p38α               Enhances apoptosis                             Cai B *et al*., *J Biol Chem,* 2006 ^[@ref-139]^                

  Caspase-3          p38α               Inhibits caspase-3 activity and\               Alvarado-Kristensson M *et al*., *J Exp Med,*\                  
                                        apoptosis                                      2004 ^[@ref-140]^                                               

  Caspase-8          p38α               Inhibits caspase-8 activity and\               Alvarado-Kristensson M *et al*., *J Exp Med,*\                  
                                        apoptosis                                      2004 ^[@ref-140]^                                               

  Caspase-9          p38α               Inhibits caspase-9 activity and\               Seifert A *et al*., *Cell Signal,* 2009 ^[@ref-141]^            
                                        apoptosis                                                                                                      

  DNA/RNA\           Cdt1               p38α, p38β                                     Increases protein stability                                     Chandrasekaran S *et al*. *, Mol Cell Biol,*\
  binding proteins                                                                                                                                     2011 ^[@ref-142]^

  Drosha             p38α               Enhances nuclear export and\                   Yang Q *et al*. *, Mol Cell,* 2015 ^[@ref-143]^                 
                                        degradation                                                                                                    

  FBP2               p38α               Promotes prothrombin mRNA 3\' end\             Danckwardt S *et al*. *, Mol Cell,* 2011 ^[@ref-144]^           
                                        processing                                                                                                     

  FBP3               p38α               Promotes prothrombin mRNA 3\' end\             Danckwardt S *et al*. *, Mol Cell,* 2011 ^[@ref-144]^           
                                        processing                                                                                                     

  H2AX               p38α, p38β         Promotes serum starvation-induced\             Lu C *et al*. *, FEBS Lett,* 2008 ^[@ref-145]^                  
                                        apoptosis                                                                                                      

  H3                 p38α               N/D                                            Zhong SP *et al*. *, J Biol Chem,* 2000 ^[@ref-146]^            

  HuR                p38α, p38β         Enhances cytoplasmic accumulation\             Lafarga V *et al*. *, Mol Cell Biol,* 2009 ^[@ref-147]^         
                                        and increases mRNA stability                                                                                   

  KSRP               p38α, p38β         Prevents KSRP-mediated ARE-directed\           Briata P *et al*. *, Mol Cell,* 2005 ^[@ref-148]^               
                                        mRNA decay                                                                                                     

  Rps27              p38α               N/D                                            Knight JD *et al*., *Skelet Muscle,* 2012 ^[@ref-149]^          

  SPF45              p38α               Inhibits Fas alternative splicing (exon 6\     Al-Ayoubi AM *et al*., *Mol Cell Biol,* 2012 ^[@ref-150]^       
                                        exclusion)                                                                                                     

  Endocytosis\       EEA1               p38α                                           Promotes recruitment to endocytic\                              Macé G *et al*. *, EMBO J,* 2005 ^[@ref-151]^
  regulators                                                                           membranes and enhances MOR\                                     
                                                                                       endocytosis                                                     

  Rabenosyn-5        p38α               Promotes recruitment to endocytic\             Macé G *et al*. *, EMBO J,* 2005 ^[@ref-151]^                   
                                        membranes and enhances MOR\                                                                                    
                                        endocytosis                                                                                                    

  GDI-2              p38α               Enhances GDI:Rab5 complex formation\           Cavalli V *et al*. *, Mol Cell,* 2001 ^[@ref-152]^              
                                        and modulates endocytosis                                                                                      

  MAPK pathway\      JIP4               p38α                                           Enhances p38 activity                                           Kelkar N *et al*. *, Mol Cell Biol,* 2005 ^[@ref-153]^
  regulator                                                                                                                                            

  Tip60              p38α               Enhances the pro-senescent function\           Zheng H *et al*. *, Mol Cell,* 2013 ^[@ref-115]^                
                                        of Tip60                                                                                                       

  TAB1               p38α               Inhibits TAK1 activity                         Cheung PC *et al*. *, EMBO J,* 2003 ^[@ref-154]^                

  TAB3               p38α               Inhibits TAK1 activity                         Mendoza H *et al*. *, Biochem J,* 2008 ^[@ref-155]^             

  FRS2               p38α               Downregulates FGF1-induced signaling           Zakrzewska M *et al*., *Int J Mol Sci,* 2019 ^[@ref-156]^       

  Membrane\          EGFR               p38α                                           Induces EGFR internalization                                    Winograd-Katz SE *et al*., *Oncogene,* 2006 ^[@ref-157]^
  proteins                                                                                                                                             

  FGFR1              p38α               Regulates translocation of exogenous\          Sørensen V *et al*., *Mol Cell Biol,* 2008 ^[@ref-158]^         
                                        FGF1 into the cytosol/nucleus                                                                                  

  Nav1.6             p38α               Promotes interaction with NEDD-4 and\          Gasser A *et al*., *J Biol Chem,* 2010 ^[@ref-159]^             
                                        protein degradation                                                                                            

  NHE1               p38α               Induces intracellular alkalinization           Khaled AR *et al*. *, Mol Cell Biol,* 2001 ^[@ref-160]^         

  PLA2               p38α               N/D                                            Börsch-Haubold AG *et al*. *, J Biol Chem,* 1998 ^[@ref-161]^   

  TACE               p38α, p38β         Increases TACE-mediated ectodomain\            Xu P *et al*. *, Mol Cell,* 2010 ^[@ref-162]^                   
                                        shedding and TGF-alpha family ligand\                                                                          
                                        release                                                                                                        

  ZAP70              p38α               Phosphorylation of ZAP70 increases\            Giardino Torchia ML *et al*. *, Proc Natl Acad Sci*\            
                                        stability of T cell receptor                   *U S A,* 2018 ^[@ref-41]^                                       

  Structure\         Caldesmon          p38α                                           N/D                                                             Hedges JC *et al*., *Am J Physiol,* 1998 ^[@ref-163]^
  proteins                                                                                                                                             

  Hsp27              p38α               N/D                                            Knight JD *et al*., *Skelet Muscle,* 2012 ^[@ref-149]^          

  Keratin 8          p38α               Regulates cellular keratin filament\           Ku NO *et al*., *J Biol Chem,* 2002 ^[@ref-164]^                
                                        reorganization                                                                                                 

  Lamin B1           p38α               Enhances lamin B1 accumulation                 Barascu A *et al*., *EMBO J,* 2012 ^[@ref-165]^                 

  Paxillin           p38α               Required for NGF-induced neurite\              Huang C *et al*., *J Cell Biol,* 2004 ^[@ref-166]^              
                                        extension of PC-12 cells                                                                                       

  Stathmin           p38δ               N/D                                            Parker CG *et al*., *Biochem Biophys Res*\                      
                                                                                       *Commun,* 1998 ^[@ref-167]^                                     

  SAP97              p38γ               Modulating the association of this\            Sabio G *et al*., *EMBO J,* 2005 ^[@ref-168]^                   
                                        protein with other cytoskeleton proteins                                                                       

  Tau                p38α, p38γ, p38δ   Enhances formation of paired helical\          Reynolds CH *et al*., *J Neurochem,*1997 ^[@ref-169]^\          
                                        filaments\                                     Ittner A *et al*., *Science,* 2016 ^[@ref-170]^                 
                                        Inhibits amyloid-β toxicity in Alzheimer\'s\                                                                   
                                        mice                                                                                                           

  Tensin1            p38α               Regulates the binding specificity of\          Hall EH *et al*. *, Mol Cell Proteomics,* 2010 ^[@ref-171]^     
                                        tensin1 to different proteins                                                                                  

  Others             DEPTOR             p38γ, p38δ                                     Enhances degradation and mTOR\                                  González-Terán B *et al*. *, Nat Commun,* 2016 ^[@ref-114]^
                                                                                       hyperactivation                                                 

  GS                 p38β               Required for subsequent\                       Kuma Y *et al*. *, Biochem J,* 2004 ^[@ref-172]^                
                                        phosphorylation to inhibit enzyme activity                                                                     

  LAMP2A             p38α               Activates chaperone-mediated\                  Li W *et al., Nat Commun,* 2017 ^[@ref-117]^                    
                                        autophagy                                                                                                      

  Parkin             p38α               Decreases its interaction with PINK1\          Chen J *et al., Cell Death Dis,* 2018 ^[@ref-173]^              
                                        and suppresses mitophagy                                                                                       

  p47 ^phox^         p38α               Promotes NADPH oxidase activation\             Makni-Maalej K *et al*. *, J Immunol,* 2012 ^[@ref-174]^        
                                        and superoxide production                                                                                      

  p62                p38γ, p38δ         Enhances mTORC1 activity                       Linares JF *et al., Cell Rep,* 2015 ^[@ref-175]^\               
                                                                                       Koh A *et al., Cell,* 2018 ^[@ref-176]^                         

  Raptor             p38β               Enhances mTORC1 activity in response\          Wu X-N *et al*. *, J Biol Chem,* 2011 ^[@ref-113]^              
                                        to arsenite stress                                                                                             

  Rpn2               p38α               Inhibits proteasome activity                   Lee SH *et al*. *, J Biol Chem,* 2010 ^[@ref-177]^              

  Siah2              p38α               Increases Siah2-mediated degradation\          Khurana A *et al*. *, J Biol Chem,* 2006 ^[@ref-178]^           
                                        of PHD3                                                                                                        
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CDK, cyclin-dependent kinase; EGFR, epidermal growth factor receptor; FBP1, far upstream binding protein; FGF1, fibroblast growth factor 1; FGFR1, fibroblast growth factor receptor 1; FRS2, fibroblast growth factor receptor substrate 2; GDI, GDP dissociation inhibitor; KSRP, hnRNPK-homology type splicing regulatory protein; MAPK, mitogen-activated protein kinase; mTORC1, mammalian target of rapamycin complex 1; NADPH, nicotinamide adenine dinucleotide phosphate; NGF, nerve growth factor; NHE1, Na ^+^/H ^+^ exchanger isoform 1; PHD3, prolyl hydroxylase 3; PLA2, phospholipase A2; SAP97, synapse-associated protein 97; TAB, transforming growth factor-β-activated protein kinase-1-binding protein; TACE, tumor necrosis factor-alpha-converting enzyme; TAK1, transforming growth factor β-activated kinase 1; TGF, transforming growth factor.

Biological functions of the p38 pathway
=======================================

Embryo development
------------------

p38α is required for embryo development, since the mouse *Mapk14* ^--/--^ embryo dies between embryonic days (E) 10.5 and 12.5 ^[@ref-118]--\ [@ref-121]^. Mutant mice with a single Thr ^180^ to Ala mutation or with the double T180A Y182F mutation are also embryonic lethal ^[@ref-122],\ [@ref-123]^. Surprisingly, given the importance of the dual phosphorylation for complete p38 activation, substitution of Tyr ^182^ with Phe results in mice that have reduced p38 signaling but are nevertheless viable ^[@ref-123]^, although this is consistent with previous studies showing that the p38 phosphorylated on Thr ^180^ alone retains some activity *in vitro* ^[@ref-37]^. Histological analysis demonstrates that p38α is required for placental angiogenesis, but not embryonic cardiovascular development, and tetraploid rescue of the placental defect in *Mapk14* ^--/--^ embryos confirmed that p38α is essential for extraembryonic development ^[@ref-120],\ [@ref-121]^. Given the important role that p38 and MK2 plays in regulating TNF-induced cell death ^[@ref-179]--\ [@ref-182]^, it is intriguing that the *Mapk14* ^--/--^ embryonic lethal phenotype is very similar to that observed in other mice with defects in the TNF death pathway. Caspase-8, FADD, and cFLIP knock-out mice also die at E10.5, and this is due to TNF-dependent endothelial cell death and disruption of the vasculature in the yolk sac ^[@ref-183],\ [@ref-184]^. Other p38 isoforms are not necessary for embryo development, but p38α and p38β have overlapping functions, as *Mapk14 ^loxp/loxp^Mapk11 ^--/--^Sox2-Cre* embryos die before E16.5 with spina bifida that correlates with neural hyperproliferation and increased apoptosis in the liver, which was not observed in *Mapk14* ^∆/∆^ *Sox2-Cre* embryos ^[@ref-185]^. Remarkably, p38α appears to have a very specific function during embryogenesis because when p38α was replaced by p38β in the *Mapk14* chromosomal locus, which thereby placed p38β under the control of the endogenous p38α promoter, it was unable to rescue the embryonic lethality induced by loss of p38α ^[@ref-185]^.

Immune responses
----------------

p38 is activated by many inflammatory stimuli, and its activity is important for inflammatory responses. Macrophage-specific deletion of *Mapk14* inhibits inflammatory cytokine production and protects mice from CLP-induced sepsis ^[@ref-186]^. p38α controls the production of inflammatory cytokines, such as TNF and IL-6, at many levels. It directly phosphorylates transcription factors, such as MEF2C ^[@ref-62],\ [@ref-186]^, and regulators of mRNA stability, such as hnRNPK-homology (KH) type splicing regulatory protein (KSRP) ^[@ref-187]^. MEF2C appears to play an anti-inflammatory role in endothelial cells *in vivo* ^[@ref-188]^. Via MK2/MK3, p38 also upregulates cytokine mRNA transcription by the serum response transcription factor (SRF) ^[@ref-189]^, and similarly, via MK2/MK3, p38 regulates mRNA stability by phosphorylating and inactivating TTP/Zfp36, a protein that promotes rapid turnover of AU-rich mRNAs, many of which are cytokine mRNAs ^[@ref-187],\ [@ref-190]^. p38 activation also induces the expression of inflammatory mediators such as COX-2, MMP9, iNOS, and VCAM-1, which are involved in tissue remodeling and oxidation regulation ^[@ref-191]--\ [@ref-194]^. The p38 pathway also regulates adaptive immunity. p38α participates in antigen processing in CD8 ^+^ cDCs ^[@ref-195]^, and ZAP70-mediated p38α/β activation is important for T cell homeostasis and function ^[@ref-18]^. In B cells, p38α is important for CD40-induced gene expression and proliferation of B cells ^[@ref-196]^, and the p38α--MEF2c axis is believed to be necessary for germinal center B (GCB) cell proliferation and survival ^[@ref-197],\ [@ref-198]^. Excessive activation of p38α has been observed in many inflammatory diseases, such as inflammatory bowel disease (IBD), asthma, rheumatoid arthritis, and steatohepatitis ^[@ref-199]--\ [@ref-201]^. The other members of the p38 family also play roles in immune responses. For example, p38γ and p38δ are required for neutrophil migration to damaged liver in non-alcoholic fatty liver disease ^[@ref-202]^ and inhibition of eukaryotic elongation factor 2 in LPS-induced liver damage ^[@ref-203]^. p38δ is required for neutrophil accumulation in acute lung injury ^[@ref-204]^. These observations, and the role that p38s play in TNF production, led to enormous pharmaceutical efforts to develop p38 inhibitors to treat chronic inflammatory diseases. However, unfortunately, these drugs were not efficacious in these diseases ^[@ref-205]^.

Cell cycle
----------

p38 has been implicated in G1 and G2/M phases of the cell cycle in several studies. The addition of activated recombinant p38α caused mitotic arrest *in vitro*, and an inhibitor of p38α/β suppressed activation of the checkpoint by nocodazole in NIH3T3 cells ^[@ref-206]^. G1 arrest caused by Cdc42 overexpression is also dependent on p38α in NIH3T3 cells ^[@ref-207]^. Besides, p38γ is specially required for gamma-irradiation-induced G2 arrest ^[@ref-208]^. The link between p38 and cell cycle control has been proposed through the regulation of several p38 substrates. Both p38α and p38γ regulate cell cycle progression via Rb but in opposite directions ^[@ref-14],\ [@ref-209]^. HBP1 represses the expression of cell cycle regulatory genes during cell cycle arrest in a p38-dependent manner ^[@ref-210]^; p53 and p21 activation by p38α prevented G1 progression through blockade of CDK activity ^[@ref-211],\ [@ref-212]^. The p38 pathway is also involved in cell cycle progress, as it is essential for self-renewal of mouse male germline stem cells ^[@ref-213]^ and its regulation of G1-length plays a role in cell size uniformity ^[@ref-214]^.

Cell differentiation
--------------------

Participation of p38 in cell differentiation has been reported in certain cell types. p38α activity is essential for neuronal differentiation in PC-12 cells and EPO-induced differentiation in SKT6 cells ^[@ref-20],\ [@ref-215]^. Treatment of 3T3-L1 fibroblasts with specific p38α/β inhibitors prevents their differentiation into adipocytes by reducing C/EBPβ phosphorylation ^[@ref-83]^, and p38α-dependent phosphorylation of MEF2C and BAF60 is critical for myogenic differentiation ^[@ref-110],\ [@ref-216]^. Intestinal epithelial cell-specific deletion of p38α also influences goblet cell differentiation in a Notch-dependent manner ^[@ref-200]^.

Cell metabolism
---------------

p38 group members participate in many cellular events related to metabolism. The p38β--PRAK axis specifically phosphorylates Rheb and suppresses mTORC1 activity under energy depletion conditions ^[@ref-22]^. DEPTOR, an inhibitor of mTORC, can be phosphorylated by p38γ and p38δ, leading to its degradation ^[@ref-123]^. Meanwhile, p38δ directly phosphorylated p62 to enhance mTORC1 activity in response to amino acids ^[@ref-175]^. In brown adipocytes, p38α functions as a central mediator in β-adrenergic-induced UCP1 expression ^[@ref-217],\ [@ref-218]^, while in white adipocytes, p38α inactivation leads to elevated white-to-beige adipocyte reprogramming and resistance to diet-induced obesity ^[@ref-219],\ [@ref-220]^. In hepatocytes, p38α controls lipolysis and protects against nutritional steatohepatitis. Thus, mice with hepatocyte-specific loss of p38α developed more severe steatohepatitis than wild type mice when fed high-fat or -cholesterol diets. Intriguingly, macrophage specific deletion of p38 had the opposite effect in the same high-fat diets and resulted in less steatohepatitis than in wild type mice, which probably reflects the inflammatory role of p38 in macrophages ^[@ref-199]^. p38α also directly phosphorylates Xbp1s to enhance its nuclear migration for maintaining glucose homeostasis in obesity ^[@ref-75]^. However, p38α also functions as a negative regulator of AMPK signaling in maintaining gluconeogenesis, and hepatic p38α could be a drug target for hyperglycemia ^[@ref-221]^. It was also reported that p38γ directly phosphorylated p62 under imidazole propionate stimulation to promote mTORC1 activity in hepatocytes ^[@ref-176]^. Interestingly, AMPK also triggers the recruitment of p38α to scaffold protein TAB1 for p38α autoactivation in human T cells ^[@ref-222]^.

Cell senescence
---------------

p38α appears to play a pivotal role in senescence. Constitutive activation of the p38 pathway by active MKK3 or MKK6 induces senescence in several cell types ^[@ref-223],\ [@ref-224]^, and p38α activity is responsible for senescence induced by multiple stimuli, such as telomere shortening ^[@ref-225],\ [@ref-226]^, H ~2~O ~2~ exposure ^[@ref-227],\ [@ref-228]^, and chronic oncogene activation ^[@ref-19],\ [@ref-223],\ [@ref-229]^. p38α/β-specific inhibitors have been successfully used to prevent cellular senescence in cultivated human corneal endothelial cells ^[@ref-230]^. Since cellular senescence is considered a defense strategy against oncogene activation, the p38 pathway plays important roles in tumorigenesis ^[@ref-231]^. Meanwhile, p38α activity is important for senescence-associated secretory phenotype (SASP), and its inhibition markedly reduces the secretion of most SASP factors, suggesting multiple roles for the p38 pathway in senescence ^[@ref-232]--\ [@ref-235]^.

Cell survival and death
-----------------------

The role of the p38 pathway in cell fate is cell type and stimulus dependent. For example, p38α becomes activated upon NGF withdrawal in PC-12 cells, and p38α activated by overexpression of MKK3 induced apoptosis in NGF differentiated PC-12 cells ^[@ref-211]^. Similarly, inhibition of p38 with PD169316 blocked NGF withdrawal-induced apoptosis in PC-12 cells ^[@ref-236],\ [@ref-237]^. The interplay between the p38 pathway and caspases, the central regulators/executors of apoptosis, is complicated because p38α activity can be elevated in a caspase-dependent manner in death stimulus treated cells ^[@ref-238],\ [@ref-239]^, and caspase activity can also be elevated in MKK6E (dominant active form) overexpressed cells ^[@ref-239],\ [@ref-240]^. In contrast, inhibition of caspase-8 and caspase-3 by p38α-mediated phosphorylation in neutrophils was also reported ^[@ref-140]^. Recent studies show that p38-activated MK2 directly phosphorylates RIPK1 in TNF-treated cells or pathogen-infected cells, limiting TNF-induced cell death ^[@ref-180]--\ [@ref-182]^. This represents an interesting link between cytokine production induced by TNF and cell death because TNF-induced MK2/MK3 phosphorylation of tristetraprolin/Zfp36 inactivates it and leads to increased stability of cytokine mRNAs ^[@ref-190]^. Aberrant p38α activity is observed in many tumor cells, and inhibition of p38α/β enhances cell death in these cells ^[@ref-241],\ [@ref-242]^.

Perspectives
============

p38 is one of the most researched of all proteins, let alone kinases, and a search in PubMed for p38 MAPK or p38 kinase returns more than 36,000 publications, which is a higher number than some proteins listed in a review of the \"top 10\" most studied genes ^[@ref-243]^. By contrast, searches for the kinases Raf and Src return about 17,000 and 25,000 hits, respectively. In 2018, there were more than 2,000 publications that mention p38, and it is clearly impractical to summarize such a vast amount of literature. As might be surmised from the preceding commentary, the studies are on a wide range of topics; however, the publications are more concentrated in some areas than others. The role of the p38 pathway in cancers (\>10,000) ^[@ref-244]--\ [@ref-246]^, inflammation (\>8,000) ^[@ref-247]--\ [@ref-249]^, and infections (\>3,600) ^[@ref-250],\ [@ref-251]^ was intensively studied. About 1,600 publications include the specific term \"p38 inhibitor\". This reflects the previously mentioned enormous interest of the pharmaceutical industry in developing p38 inhibitors to treat chronic inflammatory diseases, such as rheumatoid arthritis. Yet other publications report natural products that can activate or inhibit p38, with the ultimate aim of using them clinically ^[@ref-252]--\ [@ref-258]^. In 2011, the European Commission approved Esbriet (pirfenidone), which was described as a p38γ inhibitor, for the treatment of idiopathic pulmonary fibrosis ^[@ref-259]^. However, when this drug was approved by the FDA in 2014 for treating the same disease, it was described as a compound that acts on multiple pathways. In 2008, there were 27 clinical trials listed testing the use of p38 inhibitors in inflammatory disease settings ^[@ref-205]^, while a search today for p38 inhibitors in clinicaltrials.gov returns 44 studies for conditions as diverse as pain, asthma, cognitive impairment, rheumatoid arthritis, cancer, myelodysplastic syndrome, and depression ( [Table 5](#T5){ref-type="table"}). This indicates that there remains clinical interest in targeting the pathway and that there is therefore a need for more specific inhibitors of each of the p38 group members and more basic research to fully understand how the pathway, especially how each member of the p38 family, is utilized and regulated.

###### Clinical trials of p38 inhibitors.

  -----------------------------------------------------------------------------------------------
  Drug             Target     Condition or disease                    Status       NCT number
  ---------------- ---------- --------------------------------------- ------------ --------------
  ARRY-371797      p38        Ankylosing spondylitis                  Phase 2      NCT00811499

  ARRY-371797      p38        Dental pain                             Phase 2      NCT00542035\
                                                                                   NCT00663767

  ARRY-371797      p38        Healthy                                 Phase 1      NCT00790049

  ARRY-371797      p38        LMNA-related dilated cardiomyopathy     Phase 2      NCT02351856\
                                                                                   NCT02057341

  ARRY-371797      p38        Osteoarthritis of the knee              Phase 2      NCT01366014

  ARRY-371798      p38        Rheumatoid arthritis                    Phase 1      NCT00729209

  ARRY-614         p38 and\   Myelodysplastic syndromes               Phase 1      NCT01496495\
                   Tie2                                                            NCT00916227

  AZD7624          p38        Corticosteroid-resistant asthma         Phase 2      NCT02753764

  BIRB 796 BS      p38        Healthy                                 Phase 1      NCT02211170

  BMS-582949       p38α       Rheumatoid arthritis                    Phase 2      NCT00605735

  BMS-582949       p38α       Vascular diseases (atherosclerosis)     Phase 2      NCT00570752

  CHF6297          p38α       Chronic obstructive pulmonary\          Phase 1/2    NCT02815488
                              disease                                              

  Losmapimod\      p38α/β     Acute coronary syndrome                 Phase\       NCT01756495\
  (GS856553)                                                          1/2/3        NCT02145468\
                                                                                   NCT00910962

  Losmapimod\      p38α/β     Chronic obstructive pulmonary\          Phase 2      NCT00642148\
  (GS856553)                  disease                                              NCT01541852

  Losmapimod\      p38α/β     Depressive disorder, major              Phase 2      NCT00976560\
  (GS856553)                                                                       NCT00569062

  Losmapimod\      p38α/β     Glomerulosclerosis, focal segmental     Phase 2      NCT02000440
  (GS856553)                                                                       

  Losmapimod\      p38α/β     Pain, neuropathic                       Phase 2      NCT01110057\
  (GS856553)                                                                       NCT00969059

  LY3007113        p38        Metastatic cancer                       Phase 1      NCT01463631

  Neflamapimod\    p38α       Alzheimer's disease                     Phase 2      NCT03402659\
  (VX-745)                                                                         NCT02423200\
                                                                                   NCT02423122

  Neflamapimod\    p38α       Dementia with Lewy bodies               Recruiting   NCT04001517
  (VX-745)                                                                         

  P38 inhibitor\   p38        Rheumatoid arthritis                    Phase 2      NCT00303563\
  (4)                                                                              NCT00316771

  PF-03715455      p38α       Asthma                                  Phase 2      NCT02219048

  PF-03715455      p38α       Chronic obstructive pulmonary\          Phase 2      NCT02366637
                              disease                                              

  PF-03715455      p38α       Healthy                                 Phase 1      NCT01226693

  PH-797804        p38α/β     Rheumatoid arthritis                    Phase 2      NCT00383188\
                                                                                   NCT00620685

  Ralimetinib\     p38α/β     Adult glioblastoma                      Phase 1/2    NCT02364206
  (LY2228820)                                                                      

  Ralimetinib\     p38α/β     Advanced cancer                         Phase 1      NCT01393990
  (LY2228820)                                                                      

  Ralimetinib\     p38α/β     Epithelial ovarian cancer Fallopian\    Phase 1/2    NCT01663857
  (LY2228820)                 tube cancer Primary peritoneal cancer                

  Ralimetinib\     p38α/β     Postmenopausal metastatic breast\       Phase 2      NCT02322853
  (LY2228820)                 cancer                                               

  SB-681323        p38        Acute lung injury                       Phase 2      NCT00996840

  SB-681323        p38        Coronary heart disease                  Phase 2      NCT00291902

  SB-681323        p38        Chronic obstructive pulmonary\          Phase 1/2    NCT00564746\
                              disease                                              NCT00144859

  SB-681323        p38        Pain, neuropathic                       Phase 2      NCT00390845

  SB-681323        p38        Rheumatoid arthritis Inflammation       Phase 1/2    NCT00419809\
                                                                                   NCT00439881\
                                                                                   NCT00134693

  Talmapimod\      p38α       Bone marrow diseases\                   Phase 2      NCT00113893
  (SCIO-469)                  Myelodysplastic syndromes\                           
                              Hematologic diseases Bone marrow\                    
                              neoplasms                                            

  Talmapimod\      p38α       Multiple myeloma                        Phase 2      NCT00095680\
  (SCIO-469)                                                                       NCT00087867

  Talmapimod\      p38α       Rheumatoid arthritis                    Phase 2      NCT00043732\
  (SCIO-469)                                                                       NCT00089921

  VX-702           p38α       Rheumatoid arthritis                    Phase 2      NCT00395577\
                                                                                   NCT00205478
  -----------------------------------------------------------------------------------------------

One consequence of the massive pharmaceutical effort over the last 20 years is a large number of very specific, well-tolerated, and readily bioavailable drugs that can enable such basic research. For example, one study using a boutique panel of kinase inhibitors was able to demonstrate that 11 potent and specific p38 inhibitors synergized with Smac-mimetic drugs to kill a subset of AML leukemias, providing the strongest evidence implicating p38 in Smac-mimetic-induced killing ^[@ref-179]^. Since several of these p38 inhibitors had already been clinically trialed, this presents an opportunity to fast-track such combinations into the clinic. In our opinion, it is likely that this is where the future of p38 research and p38 inhibitors lies, in revealing the intricate web of inter-connections and inter-dependencies of this core and central regulator of cell stress. We also believe that greater efforts to genetically assess the role of p38 and p38 isoforms in the pathophysiology of inflammatory and other diseases need to be made in order to push forward the clinical application of our burgeoning knowledge.
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